Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration.

AspasiaAngelakopoulou; TinaShah; ReechaSofat; SoniaShah; Diane JBerry; JackieCooper; JuttaPalmen; IoannaTzoulaki; AndrewWong; Barbara JJefferis; +35 more... NikolasManiatis; FotiosDrenos; BrunaGigante; RebeccaHardy; Ross CLaxton; KarinLeander; AnnaMotterle; Iain ASimpson; Liam Smeeth ORCID logo; AndyThomson; ClaudioVerzilli; DianaKuh; HelenIreland; JohnDeanfield; MarkCaulfield; ChrisWallace; NileshSamani; Patricia BMunroe; MarkLathrop; F Gerry RFowkes; MichaelMarmot; Peter HWhincup; John CWhittaker; Ulfde Faire; MikaKivimaki; MeenaKumari; ElinaHypponen; ChrisPower; Steve EHumphries; Philippa JTalmud; JackiePrice; Richard WMorris; ShuYe; Juan PCasas; Aroon DHingorani; (2011) Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. European heart journal, 33 (3). pp. 393-407. ISSN 0195-668X DOI: 10.1093/eurheartj/ehr225
Copy

AIMS: To evaluate the associations of emergent genome-wide-association study-derived coronary heart disease (CHD)-associated single nucleotide polymorphisms (SNPs) with established and emerging risk factors, and the association of genome-wide-association study-derived lipid-associated SNPs with other risk factors and CHD events. METHODS AND RESULTS: Using two case-control studies, three cross-sectional, and seven prospective studies with up to 25 000 individuals and 5794 CHD events we evaluated associations of 34 genome-wide-association study-identified SNPs with CHD risk and 16 CHD-associated risk factors or biomarkers. The Ch9p21 SNPs rs1333049 (OR 1.17; 95% confidence limits 1.11-1.24) and rs10757274 (OR 1.17; 1.09-1.26), MIA3 rs17465637 (OR 1.10; 1.04-1.15), Ch2q36 rs2943634 (OR 1.08; 1.03-1.14), APC rs383830 (OR 1.10; 1.02, 1.18), MTHFD1L rs6922269 (OR 1.10; 1.03, 1.16), CXCL12 rs501120 (OR 1.12; 1.04, 1.20), and SMAD3 rs17228212 (OR 1.11; 1.05, 1.17) were all associated with CHD risk, but not with the CHD biomarkers and risk factors measured. Among the 20 blood lipid-related SNPs, LPL rs17411031 was associated with a lower risk of CHD (OR 0.91; 0.84-0.97), an increase in Apolipoprotein AI and HDL-cholesterol, and reduced triglycerides. SORT1 rs599839 was associated with CHD risk (OR 1.20; 1.15-1.26) as well as total- and LDL-cholesterol, and apolipoprotein B. ANGPTL3 rs12042319 was associated with CHD risk (OR 1.11; 1.03, 1.19), total- and LDL-cholesterol, triglycerides, and interleukin-6. CONCLUSION: Several SNPs predicting CHD events appear to involve pathways not currently indexed by the established or emerging risk factors; others involved changes in blood lipids including triglycerides or HDL-cholesterol as well as LDL-cholesterol. The overlapping association of SNPs with multiple risk factors and biomarkers supports the existence of shared points of regulation for these phenotypes.



picture_as_pdf
5-2011_eurheartj_CVBiomarker_Genetic_Colab.pdf
subject
Published Version
Available under Creative Commons: NC-ND 3.0

View Download

Explore Further

Read more research from the creator(s):

Find work associated with the faculties and division(s):

Find work associated with the research centre(s):

Find work from this publication:

Find other related resources: